Dowling & Yahnke’s Adamas Pharmaceuticals ADMS Stock Holding History

Dowling & Yahnke’s Portfolio ADMS Stock Details ADMS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q4	–	Sell	-16,000	Closed	-$79K	–	389
2021 Q3	$79K	Hold	16,000	–	–	﹤0.01%	367
2021 Q2	$84K	Buy	16,000 +3,000	+23%	+$15.5K	﹤0.01%	364
2021 Q1	$62K	Hold	13,000	–	–	﹤0.01%	336
2020 Q4	$56K	Hold	13,000	–	–	﹤0.01%	325
2020 Q3	$54K	Hold	13,000	–	–	﹤0.01%	304
2020 Q2	$33K	Hold	13,000	–	–	﹤0.01%	298
2020 Q1	$38K	Hold	13,000	–	–	﹤0.01%	288
2019 Q4	$49K	Hold	13,000	–	–	﹤0.01%	321
2019 Q3	$66K	Buy	+13,000	New	+$80.3K	0.01%	301

Dowling & Yahnke's ADMS Position: Q4 2021 in Review

Dowling & Yahnke sold out of Adamas Pharmaceuticals (ADMS) in Q4 2021, closing a stake of 16,000 shares — an estimated $79K sold.

Dowling & Yahnke first reported a position in ADMS in Q3 2019 and held it in 9 quarters. The position peaked at $84K in Q2 2021. 0 funds tracked by Wall St. Rank hold ADMS as of Q4 2021.

Dowling & Yahnke reported no remaining Adamas Pharmaceuticals position as of Q4 2021 after selling out during the quarter.
Dowling & Yahnke sold 16,000 Adamas Pharmaceuticals shares in Q4 2021, an estimated $79K.
Dowling & Yahnke first reported a position in Adamas Pharmaceuticals in Q3 2019 and held it in 9 quarters.
Dowling & Yahnke's Adamas Pharmaceuticals position peaked at $84K in Q2 2021.
0 funds tracked by Wall St. Rank held Adamas Pharmaceuticals as of Q4 2021.

Based on Dowling & Yahnke's 13F filing for Q4 2021, filed 10 Feb 2022.